Xeris Biopharma (XERS) Projected to Post Earnings on Thursday

Xeris Biopharma (NASDAQ:XERS) will likely be issuing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Xeris Biopharma to post earnings of ($0.0027) per share and revenue of $79.8330 million for the quarter. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The company had revenue of $85.81 million during the quarter, compared to the consensus estimate of $86.00 million. On average, analysts expect Xeris Biopharma to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Xeris Biopharma Stock Down 1.5%

Shares of NASDAQ:XERS traded down $0.10 on Tuesday, reaching $6.25. The company had a trading volume of 747,892 shares, compared to its average volume of 1,837,580. The firm has a market capitalization of $1.08 billion, a PE ratio of -623.88 and a beta of 0.85. The company has a current ratio of 2.19, a quick ratio of 1.57 and a debt-to-equity ratio of 16.10. The firm’s 50 day simple moving average is $5.93 and its 200-day simple moving average is $7.02. Xeris Biopharma has a 52-week low of $4.26 and a 52-week high of $10.08.

Analysts Set New Price Targets

A number of research firms recently commented on XERS. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Xeris Biopharma in a report on Monday, March 2nd. Weiss Ratings raised Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Insider Activity

In other Xeris Biopharma news, Director James Aloysius Brady sold 10,834 shares of the company’s stock in a transaction that occurred on Monday, March 30th. The stock was sold at an average price of $5.54, for a total value of $60,020.36. Following the completion of the transaction, the director owned 89,166 shares in the company, valued at $493,979.64. This represents a 10.83% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Beth Hecht sold 16,667 shares of Xeris Biopharma stock in a transaction on Friday, May 1st. The shares were sold at an average price of $6.23, for a total value of $103,835.41. Following the transaction, the insider owned 1,193,173 shares in the company, valued at approximately $7,433,467.79. This trade represents a 1.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 60,835 shares of company stock worth $367,860. Company insiders own 6.47% of the company’s stock.

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors have recently modified their holdings of the company. Corient Private Wealth LLC acquired a new position in Xeris Biopharma in the fourth quarter valued at $84,000. VARCOV Co. acquired a new stake in Xeris Biopharma during the 4th quarter worth about $243,000. Virtus Investment Advisers LLC raised its position in shares of Xeris Biopharma by 44.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock worth $291,000 after acquiring an additional 11,358 shares in the last quarter. Millennium Management LLC lifted its stake in shares of Xeris Biopharma by 63.7% in the 4th quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock valued at $6,744,000 after purchasing an additional 334,302 shares during the period. Finally, Man Group plc acquired a new position in shares of Xeris Biopharma in the 4th quarter valued at about $375,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.